From Our Partners
Wednesday, June 29, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Pandemic Influenza Vaccine Facility Dedication on Sept. 18

by Global Biodefense Staff
September 15, 2014
Texas A&M Logo

Texas A&M will join the State of Texas, biopharmaceutical company GSK and the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) this week at a dedication ceremony for the new Pandemic Influenza Vaccine Facility (PIVF).

The PIVF serves as the next milestone for the Texas A&M Center for Innovation in Advanced Development and Manufacturing (CIADM) in Bryan-College Station, one of three government-funded biodefense centers in the United States.

The CIADM was founded on a $285 million public-private partnership between the U.S. Department of Health and Human Services, and collaborating academic, commercial and State of Texas stakeholders. The center is responding to the need for rapid and flexible manufacturing to bolster the nation’s response ability in the event of a public health threat, including naturally occurring emerging infectious diseases, as well as chemical, biological and nuclear hazards.

The state-of-the-art PIVF facility is designed to supply bulk antigen to meet the U.S. Government requirements for 50 million doses of pandemic influenza vaccine within four month of a declared pandemic.

The event will be held Thursday, September 18, 2014 at the facility’s site.

Attendees for the event include Texas Governor Rick Perry; Robin Robinson, Ph.D., BARDA director and deputy assistant secretary for preparedness and response, U.S. Department of Health and Human Services; along with other representatives from the State of Texas, Texas A&M and GSK.

The PIVF is on track for completion by the end of 2015.

From Our Partners
Tags: ASPRBARDAHHSPandemicVaccines

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC